目的 探讨前列回春胶囊联合特拉唑嗪治疗Ⅲb型慢性前列腺炎患者的临床疗效。方法 选取城口县人民医院2015年1月—2018年6月收治的Ⅲb型慢性前列腺炎患者214例，每组各107例。对照组患者口服盐酸特拉唑嗪片，2.0 mg/次，1次/晚；治疗组患者在对照组的基础上口服前列回春胶囊，5粒/次，3次/d，两组患者均连续治疗3个月。观察两组患者临床疗效，同时比较治疗前后两组患者美国国立卫生研究院慢性前列腺炎症状指数（NIH-CPSI）和前列腺液（EPS）中相关细胞因子的情况。结果 治疗后，对照组和治疗组临床有效率分别为74.8%和87.9%，两组比较差异具有统计学意义（P<0.05）。治疗后，两组的疼痛评分（PS）、排尿症状评分（USS）、生活质量评分（QLS）和NIH-CPSI评分均显著降低，同组治疗前后比较差异具有统计学意义（P<0.05）；且治疗后治疗组PS、USS、QLS及NIH-CPSI评分均明显低于对照组，两组比较差异均有统计学意义（P<0.05）。治疗后，两组EPS中的肿瘤坏死因子-α（TNF-α）、增殖细胞核抗原（PCNA）、血管内皮生长因子（VEGF）和前列腺素2（PGE2）水平较治疗前均显著降低，EPS中白介素-2（IL-2）水平较治疗前升高，且治疗后治疗组EPS中相关细胞因子水平明显优于对照组，两组比较差异均有统计学意义（P<0.05）。结论 前列回春胶囊联合特拉唑嗪治疗Ⅲb型慢性前列腺炎疗效显著，可以改善患者疼痛及排尿症状，提高生活质量，具有一定的临床推广应用价值。

Objective To explore the clinical efficacy of Qianlie Huichun Capsules combined with terazosin in treatment of type Ⅲb chronic prostatitis. Methods Patients (214 cases) with type Ⅲb chronic prostatitis in Chengkou People's Hospital were randomly divided into control and treatment groups, and each group had 107 cases. Patients in the control group were po administered with Terazosin Hydrochloride Tablets, 2.0 mg/time, once every night. Patients in the treatment group were po administered with Qianlie Huichun Capsules 5 grains/time, three times daily. Patients in two groups were treated for 3 months. After treatment, the clinical efficacy was evaluated, NIH-CPSI score and expressed prostatic secretions (EPS) related factors in two groups before and after treatment were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 74.8% and 87.9%, respectively, and there was difference between two groups (P<0.05), and there were differences between two groups (P<0.05). After treatment, PS, USS, QLS, and NIH-CPSI scores in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). After treatment, PS, USS, QLS, and NIH-CPSI scores in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). After treatment, TNF-α, PCNA, VEGF, and PGE2 levels in two groups were significantly decreased, but IL-2 level were significantly increased, and the difference was statistically significant in the same group (P<0.05). And those EPS related factors in the treatment group were significantly better than those in the control group, with significant difference between two groups (P<0.05). Conclusion Qianlie Huichun Capsules combined with terazosin has clinical curative effect in treatment of type Ⅲb chronic prostatitis, and can improve pain, urination symptoms, and life quality, which has a certain clinical application value.